Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.
The FTSE 250 firm said that under the agreement, it would manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors.
It said the agreement also allowed for the group to manufacture and supply viral vector products in the future.
“This development and supply agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018,” said chief executive officer John Dawson.
“We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs.”
Dawson said the company now had a portfolio of partnerships across the development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, using lentiviral vectors.
“We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs.”
At 0819 BST, shares in Oxford Biomedica were up 1.89% at 970p.
